Drug Trial Radar · NCT05509400
Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
Last checked: Nov 20, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
813
Actual
Start
Oct 18, 2022
Primary completion
Mar 10, 2025
Study completion Jun 10, 2025
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Aug 22, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted to evaluate the efficacy and tolerability of rimegepant in a population of adults that are unsuitable for triptan medications due to a previous intolerance, lack of efficacy, or contraindication (including a history of clinically-relevant cardiovascular disease).
Conditions
- Migraine
Interventions
RimegepantDrug
DB Phase: Rimegepant 75 mg Orally Disintegrating Tablet (ODT)
PlaceboDrug
DB Phase: matching placebo
RimegepantDrug
OLE Phase: Rimegepant 75 mg ODT in association with each of the first 5 qualifying migraines
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Pain Relief at 2 Hours Post-Dose: DBT PhaseTime frame: At 2 hours post-dose
Locations
93 sites in 15 countries. Site status is shown where the registry gives one.
Clinical Research Institute
Los Angeles, California
Ki Health Partners LLC, dba New England Institute for Clinical Research
Stamford, Connecticut
Wr-Msra, Llc
Lake City, Florida
Sensible Healthcare LLC
Ocoee, Florida
Sandhill Research, LLC d/b/a Accel Research Sites Network - Ormond Clinical Research Unit
Ormond Beach, Florida
WR-Mount Vernon Clinical Research, LLC
Sandy Springs, Georgia
Collective Medical Research
Overland Park, Kansas
DelRicht Research
New Orleans, Louisiana
Boston Clinical Trials
Boston, Massachusetts
Community Clinical Research Network Inc
Marlborough, Massachusetts
Michigan Headache & Neurological Institute
Ann Arbor, Michigan
Rochester Medical Group
Rochester Hills, Michigan
DM Clinical Research - Detroit
Southfield, Michigan
Clinvest Research, LLC
Springfield, Missouri
St Charles Clinical Research
Weldon Spring, Missouri
DM Clinical Research - NY, NY
Brooklyn, New York
New York Neurology Associates
New York, New York
Montefiore Medical Center
The Bronx, New York
Headache Wellness Center, PC
Greensboro, North Carolina
Synexus Clinical Research US, Inc. - Anderson
Anderson, South Carolina
Red Star Research, LLC
Lake Jackson, Texas
DM Clinical Research
Tomball, Texas
Northwest Clinical Research Center
Bellevue, Washington
USC Clinical Trials Centre
Sippy Downs, Queensland, Australia
Alfred Hospital
Melbourne, Victoria, Australia
Klinikum Klagenfurt am Wörthersee
Klagenfurt, Carinthia, Austria
Medical University Innsbruck
Innsbruck, Tyrol, Austria
GZA Ziekenhuizen
Antwerp, Belgium
UZ Brussel
Brussels, Belgium
UZ Gent
Ghent, Belgium
Jessa Ziekenhuis
Hasselt, Belgium
Cabinet Privé Dr. Simona Sava
Saint-Nicolas, Liège, Belgium
ALPHA Recherche Clinique
Québec, Canada
University of Calgary South Health Campus
Calgary, Alberta, Canada
Aggarwal and Associates Limited
Brampton, Ontario, Canada
Clinique Neuro-Lévis
Lévis, Quebec, Canada
Alpha Recherche Clinique
Québec, Quebec, Canada
University Hospital of Southern Denmark
Esbjerg, Denmark
Danish Headache Center
Glostrup Municipality, Denmark
Hospitalsenhed Midt
Viborg, Denmark
Showing 40 of 93 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.